These data indicate that a new self‐protection mechanism of AKI is the inhibition of its progression by PRDM16, which regulates the S100A6/PKC‐η/ROS/p38MAPK and JNK pathways, and furthermore, PRDM16 represents a potential therapeutic target for AKI. This evidence concerns the gene S100A6 and acute kidney injury.